Trust Signals
Primary source: Jastreboff et al., New England Journal of Medicine, 2023, Phase 2 RCT of retatrutide.
Last reviewed: May 29, 2026.
Conflicts: FormBlends sells research-grade peptides. This page discloses that plainly and grades evidence honestly, including cases where evidence is absent.
Key Takeaways
- Retatrutide (the "reta peptide") is a 36-amino-acid, once-weekly subcutaneous peptide that agonizes GLP-1, GIP, and glucagon receptors simultaneously, making it the first triple-agonist to reach Phase 3 trials in obesity.
- In the Jastreboff et al. 2023 Phase 2 RCT (n=338 active arms), the 12 mg dose group achieved a mean 24.2% body weight reduction at 48 weeks, the largest effect reported for any weekly injectable at that stage of development.
- Retatrutide is not FDA approved as of mid-2026. All non-trial access is to an unapproved research compound with no regulatory quality assurance behind it.
- The glucagon receptor component theoretically raises energy expenditure, but its isolated human contribution has not been measured in a controlled trial. Treating that mechanism as proven efficacy is unsupported.
- Purity verification via HPLC and mass spectrometry is the single most important quality checkpoint for any retatrutide sourced outside a registered clinical trial, because the peptide's 36-residue chain creates multiple synthesis failure points.
Direct Answer: What Are Reta Peptides?
"Reta peptides" is informal shorthand for retatrutide (internal Lilly designation LY3437943), a synthetic 36-amino-acid acylated peptide that activates three metabolic receptors at once: GLP-1, GIP, and glucagon. It is the leading triple-agonist in clinical development, not yet approved by any regulatory agency, and notable for producing the largest weight loss percentages seen in a Phase 2 obesity trial to date.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What is the structure of retatrutide and why does it matter?
- How does the triple-receptor mechanism work with specific numbers?
- What does the clinical evidence actually show?
- Evidence Ledger: claim-by-claim confidence ratings
- What do most pages get wrong about reta peptides?
- How does retatrutide compare honestly to semaglutide and tirzepatide?
- What are the real side effects and their reported rates?
- Operational and label literacy: how to evaluate a retatrutide product
- Dosing reference from trial data
- FAQ
- Sources
What Is the Structure of Retatrutide and Why Does It Matter?
Retatrutide is a 36-amino-acid peptide backbone derived from a glucagon-like scaffold. Its structure is modified with a C18 fatty diacid chain attached via a linker to the peptide backbone, a design borrowed from the acylation strategy used in semaglutide. That fatty acid tail binds reversibly to albumin in the bloodstream, extending the plasma half-life to approximately 6 days, which is what enables once-weekly dosing.
The 36-residue chain is meaningfully longer than semaglutide (31 residues) and tirzepatide (39 residues). Length matters for synthesis: each additional residue represents an additional coupling step in solid-phase peptide synthesis, and longer chains have statistically more opportunities for deletion sequences, racemization, or capping failures. This is why HPLC purity matters more for retatrutide than for shorter peptides.
The peptide is resistant to DPP-4 enzyme cleavage through N-terminal amino-acid substitutions, a standard engineering strategy across this drug class to prevent rapid degradation after subcutaneous injection.
How Does the Triple-Receptor Mechanism Work With Specific Numbers?
Retatrutide's three receptor targets each do distinct metabolic work:
GLP-1 receptor: Stimulates glucose-dependent insulin secretion, slows gastric emptying, and signals satiety through vagal afferents. GLP-1 receptor agonism is the most clinically validated mechanism in this class, with multiple approved drugs (semaglutide, liraglutide) confirming the weight and glucose outcomes.
GIP receptor: Potentiates insulin secretion synergistically with GLP-1. Evidence from tirzepatide, which combines GLP-1 and GIP agonism, suggests dual agonism amplifies weight loss beyond GLP-1 alone. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) showed tirzepatide at 15 mg producing roughly 22.5% weight loss at 72 weeks in people with obesity, establishing the GLP-1 plus GIP concept in humans.
Glucagon receptor: Increases hepatic glucose production and stimulates energy expenditure by upregulating fatty acid oxidation and thermogenesis in brown adipose tissue. In preclinical models, glucagon receptor activation increases oxygen consumption and reduces liver fat. The critical honest caveat: the isolated caloric-expenditure contribution of the glucagon component in retatrutide's human data has not been reported. We know the triple combination produces a larger effect than dual agonism in the Phase 2 data, but the glucagon receptor's specific share of that effect in humans is inferred, not measured.
Retatrutide's in vitro potency at each receptor was reported in preclinical Lilly publications as balanced co-agonism, meaning it is not heavily weighted to one receptor over another, unlike some earlier experimental compounds that were predominantly glucagon agonists with partial GLP-1 activity.
What Does the Clinical Evidence Actually Show?
The pivotal human evidence is one Phase 2 RCT. Jastreboff et al. published in the New England Journal of Medicine (July 2023) a 48-week, randomized, double-blind, placebo-controlled trial in 338 participants with obesity (BMI 30 or greater) but without type 2 diabetes. Participants received retatrutide at 1 mg, 4 mg, 8 mg, or 12 mg once weekly, or placebo.
Key efficacy results at 48 weeks:
- 1 mg group: approximately 8.7% mean body weight reduction
- 4 mg group: approximately 17.1% mean body weight reduction
- 8 mg group: approximately 22.8% mean body weight reduction
- 12 mg group: approximately 24.2% mean body weight reduction
- Placebo: approximately 2.1% mean body weight reduction
A separate arm of the same trial enrolled participants with type 2 diabetes, where weight loss was somewhat lower (consistent with the known attenuated response in this population seen with other agents in the class).
Phase 3 (TRIUMPH program) is ongoing as of mid-2026. No Phase 3 efficacy data are publicly available yet. Everything above about retatrutide's weight effect is Phase 2 only.
Evidence Ledger: Claim-by-Claim Confidence Ratings
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Retatrutide produces roughly 24% body weight loss at 12 mg over 48 weeks in obesity without diabetes | Phase 2 RCT (Jastreboff et al. 2023, NEJM) | Strong reduction | Moderate (Phase 2 only; n limited; Phase 3 pending) |
| GLP-1 receptor agonism reduces appetite and slows gastric emptying | Multiple Phase 3 RCTs across drug class | Consistent reduction | High |
| GIP receptor co-agonism adds to weight loss beyond GLP-1 alone | Phase 3 RCT (tirzepatide, SURMOUNT-1) | Additive benefit | Moderate (inferred from tirzepatide, not isolated in retatrutide arms) |
| Glucagon receptor agonism raises energy expenditure in humans | Animal models, mechanistic studies, very limited human data | Directionally positive | Low (human quantification not established) |
| Retatrutide preserves lean muscle mass better than GLP-1 monotherapy | Animal data only; no human controlled trial | Speculative | Very Low |
| Once-weekly dosing is feasible via albumin-binding acylation | Phase 2 PK data (Lilly) | Confirmed | High |
| GI adverse events (nausea, vomiting) are common at higher doses | Phase 2 RCT safety data (Jastreboff et al. 2023) | Frequent at 8-12 mg | High for the drug class direction; Moderate for exact rates from single trial |
| Retatrutide reduces liver fat in people with metabolic dysfunction | Phase 2 NASH/MAFLD subgroup data (Lilly, presented 2024) | Positive direction | Low (subgroup, not primary endpoint) |
What Do Most Pages Get Wrong About Reta Peptides?
This is the section commodity pages skip.
1. Treating Phase 2 numbers as settled efficacy. Nearly every blog states "retatrutide causes 24% weight loss" as though that is a confirmed, reproducible, regulatory-grade number. Phase 2 trials are optimized for dose-finding, not for final efficacy confirmation. The 12 mg arm in Jastreboff 2023 had a limited sample. Phase 3 routinely produces more modest numbers than Phase 2 for this class of drug, partly due to larger, more diverse populations and tighter compliance monitoring.
2. Ignoring the glucagon receptor safety question. Glucagon receptor activation raises hepatic glucose production. In people with poorly controlled type 2 diabetes, this is not a trivial concern. The net metabolic effect in the trial was beneficial because GLP-1-driven insulin secretion offset the glucagon-driven glucose rise in a glucose-dependent way, but that balance depends on intact beta-cell function. In someone with advanced diabetes and limited insulin reserve, the calculus changes. Almost no lay page discusses this.
3. Conflating research-compound retatrutide with the trial drug. The retatrutide used in Lilly's clinical trial is pharmaceutical-grade, manufactured under GMP, with verified sequence, purity, sterility, and endotoxin testing. Research-grade retatrutide purchased from a peptide vendor has none of those guarantees unless independent COA documentation is provided. Sequence errors (wrong amino acid at any of 36 positions), truncation peptides, and endotoxin contamination are real failure modes that would change both safety and efficacy. Blogs treat the two as interchangeable; they are not.
4. The bioavailability problem is never mentioned. Retatrutide, like all peptides in this class, has essentially zero oral bioavailability. It must be injected subcutaneously. Any "oral" or "sublingual" retatrutide product is degraded in the GI tract before reaching systemic circulation. No approved or investigational oral form of retatrutide exists as of mid-2026.
5. Stability after reconstitution is poorly understood outside GMP conditions. The Phase 2 trial used pharmaceutical vials with defined shelf life and cold-chain tracking. For reconstituted research peptide stored in a vial at home, the stability window is not established by peer-reviewed data. General peptide chemistry suggests refrigeration and use within a few weeks of reconstitution is prudent, but the specific degradation kinetics for retatrutide's acylated 36-residue structure in bacteriostatic water at 4 degrees Celsius have not been published in an accessible peer-reviewed source. This uncertainty is real.
How Does Retatrutide Compare Honestly to Semaglutide and Tirzepatide?
| Feature | Semaglutide (Wegovy) | Tirzepatide (Zepbound) | Retatrutide (LY3437943) |
|---|---|---|---|
| Receptor targets | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Regulatory status | FDA approved (obesity, T2D, CV) | FDA approved (obesity, T2D) | Not approved; Phase 3 |
| Peak weight loss (best trial arm) | Approx. 14-15% at 68 weeks (STEP 1) | Approx. 22.5% at 72 weeks (SURMOUNT-1) | Approx. 24.2% at 48 weeks (Phase 2 only) |
| Evidence level | Multiple Phase 3 RCTs, real-world data | Multiple Phase 3 RCTs | One Phase 2 RCT; Phase 3 ongoing |
| CV outcome data | Yes (SELECT trial, NEJM 2023) | SURPASS-CVOT positive (2025) | No outcome data |
| GI side-effect profile | Moderate; well-characterized | Moderate; similar to semaglutide | Moderate to high at top doses; less characterized |
| Lean mass data in humans | Loss of lean mass documented | Loss of lean mass documented | Not yet reported in human trial |
| Availability | Prescription; compounded forms common | Prescription; compounded forms common | Research compound only outside trials |
| Where retatrutide loses | N/A | N/A | No approval, no outcome data, no long-term safety data, uncertain compound quality outside trials |
What Are the Real Side Effects and Their Reported Rates?
From the Jastreboff et al. 2023 Phase 2 RCT, gastrointestinal events were the dominant adverse effect category. Nausea, vomiting, diarrhea, and constipation were each reported in a substantial minority to majority of participants in the higher-dose arms. The published paper provides specific percentages by dose arm; the consistent pattern was dose-dependent incidence, meaning the 12 mg arm had higher rates than the 4 mg arm.
Heart rate increase (a known class effect related to GLP-1 and glucagon receptor activation) was observed. Injection site reactions (erythema, pruritus) were reported in a minority of participants.
Gallbladder-related adverse events, including cholelithiasis, occurred in a minority of participants, consistent with the class effect seen with other GLP-1 agonists (rapid weight loss increases biliary cholesterol saturation).
No cases of pancreatitis were specifically highlighted as a signal in the Phase 2 safety report, though pancreatitis is a labeled warning for the drug class and Phase 3 safety monitoring continues.
Operational and Label Literacy: How to Evaluate a Retatrutide Product
If you are evaluating retatrutide as a research compound, here is what to verify before use.
Certificate of Analysis (COA) checklist:
| Test | What to Look For | Red Flag |
|---|---|---|
| HPLC purity | Greater than 98% (research grade) | Purity below 95% or no HPLC data at all |
| Mass spectrometry | Molecular weight matching approximately 4,444 Da (the expected MW for retatrutide) | Missing MS data or MW discrepancy |
| Endotoxin | Below 1 EU/mg (LAL test or equivalent) | No endotoxin testing reported |
| Sterility or bioburden | Tested and documented | No sterility data |
| Sequence confirmation | Amino acid sequence verified (reported in COA or by sequencing) | Sequence assumed from synthesis order, not analytically confirmed |
Reconstitution: Use bacteriostatic water (not sterile water, which lacks preservative for multi-use vials). A common reconstitution volume is 1 to 2 mL per vial depending on the stated peptide mass. Example: a 5 mg vial reconstituted with 1 mL gives a 5 mg/mL solution; 0.5 mL per injection delivers 2.5 mg. Always use an insulin syringe (U-100) for precision at sub-milligram doses.
What a degraded product looks like: A properly reconstituted retatrutide solution should be clear and colorless to very pale yellow with no visible particulate matter. Cloudiness, significant color change, or particulate matter after reconstitution are signs of degradation or contamination. Discard and do not inject.
Storage: Unreconstituted lyophilized peptide: freezer (minus 20 degrees Celsius) for long-term, refrigerator (2 to 8 degrees Celsius) for near-term use. After reconstitution: refrigerate only, do not refreeze. Avoid repeated temperature cycling.
Dosing Reference From Trial Data
| Phase 2 Dose Arm | Starting Dose | Target Dose | Dosing Frequency | Mean Weight Loss at 48 Weeks |
|---|---|---|---|---|
| Low | 1 mg | 1 mg | Once weekly SC | Approx. 8.7% |
| Mid-low | Escalating | 4 mg | Once weekly SC | Approx. 17.1% |
| Mid-high | Escalating | 8 mg | Once weekly SC | Approx. 22.8% |
| High | Escalating | 12 mg | Once weekly SC | Approx. 24.2% |
These doses are from a controlled clinical trial. They are not prescriptive guidance for research use. Dose escalation in the trial followed a structured schedule designed to minimize GI side effects; starting at the target dose without escalation was not studied and would be expected to increase adverse event rates.
FAQ
What are reta peptides?
"Reta peptides" is shorthand for retatrutide (LY3437943), a synthetic 36-amino-acid acylated peptide developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors. It is the first triple-agonist in advanced clinical trials for obesity and type 2 diabetes.
How is retatrutide different from semaglutide?
Semaglutide activates GLP-1 receptors only. Retatrutide adds GIP and glucagon receptor co-agonism. In the Phase 2 data, this triple mechanism produced approximately 24% body weight reduction versus semaglutide's approximately 15% at its highest approved weekly dose in Phase 3 trials. However, semaglutide has multiple Phase 3 RCTs and cardiovascular outcome trial data; retatrutide has neither.
What does the glucagon receptor component of retatrutide actually do?
Glucagon receptor activation increases hepatic glucose output and is theorized to raise basal metabolic rate by stimulating fatty acid oxidation and thermogenesis. This is a plausible mechanism supported by preclinical data. The precise additional caloric contribution in humans has not been isolated. In the presence of GLP-1-driven insulin secretion, the net glucose effect is blunted in people with functional beta cells.
What was the weight loss seen in the retatrutide Phase 2 trial?
In the Jastreboff et al. 2023 Phase 2 RCT published in the New England Journal of Medicine, participants on 12 mg weekly achieved a mean 24.2% reduction in body weight at 48 weeks in people with obesity without diabetes. The trial enrolled 338 participants across all active arms.
Is retatrutide FDA approved?
No. As of mid-2026, retatrutide is not FDA approved. It is in Phase 3 clinical trials. Any retatrutide available outside a registered clinical trial is a research-use compound with no regulatory approval for human therapeutic use.
What are the main side effects of retatrutide?
In the Phase 2 trial, gastrointestinal events (nausea, vomiting, diarrhea, constipation) were the most common adverse effects, predominating in higher-dose arms. Injection-site reactions, decreased appetite, increased heart rate, and gallbladder-related events were also reported in a minority of participants.
How is retatrutide dosed?
In the Phase 2 trial, retatrutide was administered subcutaneously once weekly with dose escalation starting at lower doses and titrating to a maximum of 12 mg. Escalation reduces gastrointestinal adverse events during initiation. No fixed-dose protocol outside the clinical trial has been validated.
What does retatrutide look like as a research compound and how should it be stored?
Research-grade retatrutide is typically supplied as a lyophilized white to off-white powder requiring reconstitution with bacteriostatic water. Store unreconstituted vials at minus 20 degrees Celsius for long-term storage or at 2 to 8 degrees Celsius for near-term use. After reconstitution, refrigerate and do not refreeze. Discard if the solution is cloudy or contains particulate matter.
Does retatrutide affect muscle mass?
The Jastreboff et al. 2023 Phase 2 trial did not separately report lean mass changes. Animal data suggest glucagon receptor co-agonism may help preserve lean mass during caloric restriction. This has not been confirmed in a human controlled trial. Treating retatrutide as muscle-sparing based on preclinical data alone is premature.
How do you read a retatrutide certificate of analysis?
A valid COA should report HPLC purity greater than 98% for research grade, mass spectrometry confirming the molecular weight (approximately 4,444 Da), and endotoxin testing below 1 EU/mg. Missing any of these three data points is a sourcing red flag. Sequence confirmation by analytical method, not just synthesis record, is the gold standard.
Can retatrutide be used alongside other peptides or drugs?
No combination use has been studied in controlled human trials. Combining retatrutide with other GLP-1 agonists is redundant and likely to increase adverse events. Combination with insulin secretagogues carries hypoglycemia risk. All combination protocols outside a registered clinical trial are unvalidated and not endorsed by published evidence.
Sources
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023;389(6):514-526. PMID 37366315.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216. PMID 35658024.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023;389(24):2221-2232. PMID 37952131.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002. PMID 33567185.
- Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nature Medicine. 2015;21(1):27-36. PMID 25485909. (Foundational preclinical triple-agonist concept.)
- US FDA. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Accessed 2026. FDA.gov.
- Eli Lilly and Company. TRIUMPH Phase 3 Program (Retatrutide). ClinicalTrials.gov identifiers NCT05929079 and related. Accessed 2026.
Footer Disclaimers
Related peptide guides
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →